Myrlene Sanon, MPH

i3 Innovus
Health Economics and Outcomes Research
10 Cabot Road
Suite 304
Medford, MA
USA 02124

Biographical Sketch:
Ms. Sanon joined i3Innovus as a Research Analyst in March 2008. She graduated from Boston University School of Public Health with a concentration in epidemiology; areas of focus include pharmacoepidemiology and clinical study designs. Prior to joining i3, Ms. Sanon was a lead research assistant with the pulmonary department at Boston University School of Medicine conducting randomized clinical trial asthma studies. Ms. Sanon has relevant experience in the following areas; Clinical research, data management, investigating, and using existing resources to identify disease frequencies, and performing statistical analyses. While with i3, Ms. Sanon has extensive experience using SEER, SEER-Medicare linked data, and SAS to assess the epidemiologic and economic burden of Gastrointestinal stromal tumors (GIST). She has also performed disease burden analyses using SEER in, but not limited to, the following disease areas; Breast cancer, Non-Hodgkin Lymphoma, Glioblastoma multiforme (GBM), Cutaneous T cell lymphoma (CTLC), and Head and Neck Cancers. Ms. Sanon has programmed a comprehensive model to examine the cost-effectiveness of HPV vaccination in the prevention of non-cervical cancers that include vulvar, vaginal, penile, anal, and oral cancers. Furthermore, Ms. Sanon has experience using survey data National Health Interview Survey (NHIS) for analyses relating to cervival cancer screening and National Health and Nutrition Examination Survey (NHANES). Numerous poster presentations Publications Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.Jaime L Rubin; Douglas C A Taylor; Myrlene Sanon; John H Coombs; Vamsi K Bollu.JMCP.2010;16:482-91